DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY
ORIGINAL ARTICLE
Morbidity and medication in a large population of individuals with Down syndrome compared to the general population MYRIAM ALEXANDER 1
| HANS PETRI 2 | YINGJIE DING 3 | CHRISTOPH WANDEL 4 | OMAR KHWAJA 5 |
NADIA FOSKETT 1 1 Roche Products Limited, Welwyn Garden City; 2 Petri Consulting Ltd, St Albans, UK; 3 Genesis Research Limited Hoboken, NJ, USA; 4 Roche Product Development Basel; 5 Roche Pharmaceutical Research and Early Development, Basel, Switzerland. Correspondence to Nadia Foskett at Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, UK. E-mail:
[email protected]
PUBLICATION DATA
Accepted for publication 2nd July 2015. Published online 18th August 2015. ABBREVIATIONS
CPRD IRR YPR
Clinical Practice Research Datalink Incidence rate ratio Yearly prevalence ratio
AIM The aim of this study was to describe the incidence of morbidities and the prevalence of medical prescriptions in a large Down syndrome population. METHOD A retrospective cohort study was carried out using the UK Clinical Practice Research Datalink from 1 January 2004 to 31 December 2013. We matched individuals with Down syndrome to randomly selected control participants by practice site, sex, birth year, and recording period. RESULTS A total of 6430 individuals with Down syndrome (3009 females, 3421 males) and 19 176 controls (8966 females, 10 210 males) were included in the study. The incidence of cardiovascular disorders, gastrointestinal diseases (incidence rate ratio [IRR] 7.9 at 3 to
